PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF OAT1/3 ACTIVITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

被引：0
|
作者：
Dubinsky, S. [1 ]
Malik, P. [1 ]
Edginton, A. [1 ]
机构：
[1] Univ Waterloo, Waterloo, ON, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-054
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF CREATININE-DRUG INTERACTION IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S113 - S114
  • [2] Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment
    Tan, Shawn Pei Feng
    Scotcher, Daniel
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 643 - 652
  • [3] Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population
    Takita, Hiroyuki
    Scotcher, Daniel
    Chinnadurai, Rajkumar
    Kalra, Philip A.
    Galetin, Aleksandra
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (12): : 695 - 706
  • [4] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO SUPPORT DOSING OF ORAL PARICALCITOL IN PEDIATRIC POPULATIONS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.
    Basu, S.
    Dufek, M. B.
    Mostafa, N. M.
    Shebley, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S59 - S59
  • [5] Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling
    Dubinsky, Samuel
    Malik, Paul
    Hajducek, Dagmar M.
    Edginton, Andrea
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 997 - 1012
  • [6] Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling
    Samuel Dubinsky
    Paul Malik
    Dagmar M. Hajducek
    Andrea Edginton
    [J]. Clinical Pharmacokinetics, 2022, 61 : 997 - 1012
  • [7] Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
    Yang, Yujie
    Wang, Yirong
    Zeng, Wei
    Zhou, Jinhua
    Xu, Min
    Lan, Ying
    Liu, Lvye
    Shen, Jian
    Zhang, Chuan
    He, Qin
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [8] Physiologically based pharmacokinetic modeling to predict OAT3-mediated drug-drug interactions of meropenem in varying stages of chronic kidney disease
    Dong, Jing
    Liu, Jinyao
    Liu, Yanhui
    Yao, Jiachen
    Lu, Yan
    Jiao, Zheng
    Li, Wenyan
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 183
  • [9] Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models
    Zamir, Ammara
    Alqahtani, Faleh
    Rasool, Muhammad Fawad
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (1-2) : 95 - 105
  • [10] Application of physiologically-based pharmacokinetic modeling to inform dosing decisions for geriatric patients
    Qian, Lixuan
    Wang, Ziteng
    Paine, Mary F.
    Chan, Eric Chun Yong
    Zhou, Zhu
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024,
12345